Everything tagged "healthcare plans" across the TickerSpark archives.
UnitedHealth is working through a margin recovery as Optum improves and medical costs ease. The stock looks attractive on valuation, but execution and utilization risk still matter.
Molina Healthcare faces a sharp 2026 earnings reset, but Medicaid rate normalization and improving Medicare duals could support a 2027 rebound. The stock looks more like a Hold than a Buy while execution risk remains high.
Elevance Health shows a credible medium-term recovery story, supported by valuation and cash flow, but Medicaid pressure and earnings volatility keep the stock at Hold. The report highlights improving Medicare Advantage economics, Carelon expansion, and a 2027 EPS growth target, offset by near-term execution risk.
Humana’s Buy case hinges on a rebound in Medicare Advantage economics, improving operating efficiency, and CenterWell growth. The stock still faces meaningful reimbursement, Star Ratings, and medical cost risk.
Centene is showing real margin-recovery progress after a difficult 2025, but Medicaid, Marketplace, and Medicare cost pressure still make this a Hold. Q1 2026 results and raised guidance support the turnaround, though the stock already trades near consensus value.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime